Apr 02, 2024
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Apr 02, 2024
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Apr 27, 2020
Photocure Regains Worldwide Rights of Hexvix
Oct 15, 2019
Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) for the First-Line Treatment of Adults with Advanced Renal Cell Carcinoma
Jul 02, 2019
A2A Pharmaceuticals Appoints Dr. Sotirios Stergiopoulos Chief Executive Officer
Jun 27, 2019
CB-839 (Calithera Biosciences) Drug Overview 2019: CB-839 will be the First Glutaminase Inhibitor Approved for the Treatment of Renal Cell Carcinoma
Jun 05, 2019
Ipsen's Dysport® (Clostridium Botulinum Type a Toxin-haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration by Healthcare Professionals, Such as Physiotherapists, in the UK
May 30, 2019
Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
Apr 04, 2019
Servier and Ipsen Join Access Accelerated to Fight Growing NCD Burden
Mar 07, 2019
Clementia Pharmaceuticals Inc. obtains interim order for proposed transaction with Ipsen S.A. and enters into support and voting agreements with two additional significant shareholders
Nov 19, 2018
Ipsen Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Nov 08, 2018
Ipsen to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018
Sep 19, 2018
Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma
Feb 13, 2018
Health Canada approves Ipsen's Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Sep 05, 2017
Ipsen Biopharmaceuticals Canada Names Paul Reider Country Manager and Joins Innovative Medicines Canada to Drive Development and Delivery of Key Therapies
Sep 05, 2017
Innovative Medicines Canada welcomes Akcea Therapeutics Canada and Ipsen Biopharmaceuticals Canada as its newest members